Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

BridgeBio Pharma, Inc. (BBIO)

We couldn't retrieve the full text for this release. Read it on the company's site.